Remove 2025 Remove Documentation Remove Labelling
article thumbnail

The Great RIF(T): One FDA Division’s Destruction and What it Could Mean for Generic Drugs

The FDA Law Blog

Indeed, since 2014, DPD facilitatedthe publication of 42 quarterly batches and dozens of stand-alone PSGs, plus three one-off batches of PSGs updated to align with recommendations in general guidance documents ( g. , Under GDUFA III alone, DPD published 32 GDUFA guidance documents and MAPPs to ensure the successful implementation of GDUFA.

FDA 141
article thumbnail

FDA Publishes Proposal to Redefine the Implied Nutrient Contain Claim “Healthy” Changing Focus to Foods Rather than Nutrients Adding Limits on Added Sugar Content

The FDA Law Blog

In 2015, FDA issued a Warning Letter to Kind LLC because, among other things, the company labeled products as healthy whereas these products provided more saturated fat per serving than permitted by the regulatory definition. It is focused on the nutrients in the food product rather than on it overall nutritional “quality.”.

FDA 52
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Developing the EU’s first intestinal microbiota-based biologic

European Pharmaceutical Review

This randomised, open label-controlled multicentre clinical trial was conducted across 21 sites in Spain from 2021 to 2023. European Society of Clinical Microbiology and Infectious Diseases: 2021 update on the treatment guidance document for Clostridioides difficile infection in adults.

article thumbnail

Finalizing the Quality Management System Regulation – A High Priority for End of 2023

The FDA Law Blog

In fact, the priority designation for the final rule is labeled as “economically significant.” Finally, CDRH would need to ensure alignment on existing guidance documents and regulations that refer to the QSR or 21 C.F.R. Dr. Shuren further elaborated that he hopes the final rule will be “out by the end of this year.”

FDA 52
article thumbnail

The Rise of eSTAR for Medical Device De Novo Submissions

The FDA Law Blog

It also presents specific questions to collect data from the submitter and provides links to relevant regulations and guidance documents. The draft guidance indicates that this timetable will be announced by September 30, 2025. These content elements precisely follow the De Novo request content described in 21 C.F.R.

FDA 52
article thumbnail

How much does semaglutide cost per month?

The Checkup by Singlecare

If your healthcare provider prescribes Ozempic for weight management, which is an off-label use, insurance isnt as likely to cover it. Restrictions on off-label use: Insurance plans may not cover a medication prescribed off-label , that is, if its not prescribed for its FDA-approved use. affected by a shortage).

article thumbnail

How much is Paxlovid without insurance?

The Checkup by Singlecare

For example, in 2025, Aetnas Standard Plan and Humanas Medicare Advantage Plan include Paxlovid in their formularies. The drugs label states that it is indicated for COVID-19 treatment only and not prophylaxis against it. Coverage of Paxlovid by insurance plans is unpredictable and differs from one plan to another.